SMARCA4 and neuroendocrine neoplasm: While BRG1 loss was observed to be between 15-30% in adenocarcinoma and squamous cell carcinoma, the two predominant histologic subtypes of non-small cell lung cancer (NSCLC), we observed a low rate of BRG1 loss in other lung cancer histologies such as bronchioloalveolar carcinoma (BAC), and the neuroendocrine tumors (small cell lung cancer, large cell, carcinoid and atypical carcinoid) [33] (Supplementary Table 2B and 2C).